Fears of border delays and complications in a post-Brexit UK have led to the French pharmaceutical company increasing its contingency stockpiles by four weeks to enable a 14-week supply of
AstraZeneca is selling off European commercial rights to its high blood pressure drug Atacand to German biotech Cheplapharm, securing $200 million for “company’s new wave of medicines”.
MedImmune, the R&D arm of AstraZeneca has teamed up with California based 4DMT, a next-generation virus-based gene therapy research house developing a treatment for chronic lung disease
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
